ERS Medical

Belkins
ERS Medical provides a range of specialist patient transport and courier services along with innovative Patient Communication solutions to the NHS and the wider healthcare sector. ERS Medical also offers mobile event medical cover for a wide number of sporting venues and events. Additionally, ERS Medical provides a comprehensive selection of training and higher education courses for people that work or want to work within the pre-hospital care sector.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CELL AND GENE THERAPY

VIZGEN RELEASES COMMERCIAL MERSCOPE PLATFORM

Vizgen | August 31, 2021

news image

Vizgen, the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, today announced shipment of the first commercial MERSCOPETM Platforms, marking the successful start of their limited summer release program. These first platforms are being purchased by leading research institutes including the Salk Institute, the University of California, Irvine, and the Beth Israel Deaconess Medical Center. Vizgen will continue shipping a limited number...

Read More

MEDICAL

NANOFORM LAUNCHES TECHNOLOGY THAT CAN FORM BIOLOGICAL NANOPARTICLES AS SMALL AS 50 NM AND NEW NEAR-TERM BUSINESS TARGET FOR 2021

Nanoform | November 27, 2020

news image

Nanoform Finland Plc ("Nanoform"), an innovative nanoparticle medication empowering organization, today reported a proprietary technology that can frame biological nanoparticles as small as 50 nm and declared another close term business focus for 2021 to convey its first biologics Proof of Concept project for this new technology with a pharmaceutical or biotech partner. As drug molecules become more complex so do the alternatives to convey them. This complex nanoparticle...

Read More

CELL AND GENE THERAPY

SARTORIUS STEDIM BIOTECH STRENGTHENS ITS PRODUCT PORTFOLIO FOR CELL AND GENE THERAPIES BY ACQUIRING A MAJORITY STAKE IN CELLGENIX

Sartorius | July 05, 2021

news image

Sartorius Stedim Biotech, a leading international biopharmaceutical partner, has acquired a majority stake in CellGenix GmbH, a reagent manufacturer. The company, headquartered in Freiburg, Germany, and with a sales subsidiary near the biotechnology center in Boston, Massachusetts, USA, manufactures and distributes cell culture components in GMP grade for the manufacture of cell and gene therapy products. Sartorius Stedim Biotech originally purchased 51% of this company, which was...

Read More

RESEARCH

CEDILLA THERAPEUTICS EXPANDS LEADERSHIP TEAM WITH KEY APPOINTMENTS ACROSS R&D AND FINANCE

Cedilla Therapeutics | November 17, 2021

news image

Cedilla Therapeutics, a biotechnology company bringing a new dimension to precision oncology, announced appointments across its research and development (R&D) and finance teams, including Joshua Murtie, Ph.D., as Vice President of Biology and Chris Lindblom as Vice President of Finance. These hires are part of an ongoing initiative to expand Cedilla’s leadership and enable future growth as the company progresses its lead programs, conditional inhibitors of TEAD and CDK2, toward the cli...

Read More
news image

CELL AND GENE THERAPY

VIZGEN RELEASES COMMERCIAL MERSCOPE PLATFORM

Vizgen | August 31, 2021

Vizgen, the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, today announced shipment of the first commercial MERSCOPETM Platforms, marking the successful start of their limited summer release program. These first platforms are being purchased by leading research institutes including the Salk Institute, the University of California, Irvine, and the Beth Israel Deaconess Medical Center. Vizgen will continue shipping a limited number...

Read More
news image

MEDICAL

NANOFORM LAUNCHES TECHNOLOGY THAT CAN FORM BIOLOGICAL NANOPARTICLES AS SMALL AS 50 NM AND NEW NEAR-TERM BUSINESS TARGET FOR 2021

Nanoform | November 27, 2020

Nanoform Finland Plc ("Nanoform"), an innovative nanoparticle medication empowering organization, today reported a proprietary technology that can frame biological nanoparticles as small as 50 nm and declared another close term business focus for 2021 to convey its first biologics Proof of Concept project for this new technology with a pharmaceutical or biotech partner. As drug molecules become more complex so do the alternatives to convey them. This complex nanoparticle...

Read More
news image

CELL AND GENE THERAPY

SARTORIUS STEDIM BIOTECH STRENGTHENS ITS PRODUCT PORTFOLIO FOR CELL AND GENE THERAPIES BY ACQUIRING A MAJORITY STAKE IN CELLGENIX

Sartorius | July 05, 2021

Sartorius Stedim Biotech, a leading international biopharmaceutical partner, has acquired a majority stake in CellGenix GmbH, a reagent manufacturer. The company, headquartered in Freiburg, Germany, and with a sales subsidiary near the biotechnology center in Boston, Massachusetts, USA, manufactures and distributes cell culture components in GMP grade for the manufacture of cell and gene therapy products. Sartorius Stedim Biotech originally purchased 51% of this company, which was...

Read More
news image

RESEARCH

CEDILLA THERAPEUTICS EXPANDS LEADERSHIP TEAM WITH KEY APPOINTMENTS ACROSS R&D AND FINANCE

Cedilla Therapeutics | November 17, 2021

Cedilla Therapeutics, a biotechnology company bringing a new dimension to precision oncology, announced appointments across its research and development (R&D) and finance teams, including Joshua Murtie, Ph.D., as Vice President of Biology and Chris Lindblom as Vice President of Finance. These hires are part of an ongoing initiative to expand Cedilla’s leadership and enable future growth as the company progresses its lead programs, conditional inhibitors of TEAD and CDK2, toward the cli...

Read More